- Home
- BLLN vs ACLX Comparison
BLLN vs ACLX Comparison
Compare BLLN & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLLN | ACLX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | BLLN | ACLX |
|---|---|---|
| Price | $77.41 | $113.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 15 |
| Target Price | ★ $137.83 | $115.85 |
| AVG Volume (30 Days) | 212.0K | ★ 3.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | $98.01 | $480.59 |
| Revenue Next Year | $36.76 | $88.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $66.00 | $47.86 |
| 52 Week High | $138.70 | $114.26 |
Technical Indicators
Market Signals| Indicator | BLLN | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 83.63 |
| Support Level | N/A | $64.61 |
| Resistance Level | $100.28 | $114.26 |
| Average True Range (ATR) | 7.24 | 1.84 |
| MACD | -1.04 | 4.89 |
| Stochastic Oscillator | 38.55 | 99.50 |
Price Performance
Historical ComparisonAbout BLLN BillionToOne Inc.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.